Shares of NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) rose 12.71% to $3.37 in pre-event trading as the company’s subsidiary, HOPE Therapeutics, Inc., announced a pivotal investor workshop. This event targets Qualified Institutional Investors and aims to support the acquisition of interventional psychiatry clinics specializing in treatments for suicidal depression and PTSD.
Strategic Acquisitions for Expanding Psychiatry Network
HOPE Therapeutics has revealed non-binding Letters of Intent and preliminary financing agreements for the purchase of clinics that are anticipated to bring in more than $100 million annually by 2025. Facilities with proven patient bases and multimodal care services, such as ketamine therapy and transcranial magnetic stimulation (TMS), are the emphasis of the company’s acquisition strategy.
David Feifel, MD, PhD, the appointed Chief Medical Innovation Officer, and Jonathan Javitt, MD, MPH, Chairman and Co-CEO of HOPE Therapeutics, will be in charge of the investor event. They will provide updates on tNRx Pharmaceuticals’ roadmap and answer questions regarding upcoming acquisitions. The workshop is scheduled for the week of January 6, 2025, with participation limited to institutional investors prepared to commit at least $5 million in secured acquisition funding.
Kadima Neuropsychiatry Institute Acquisition Announced
As part of its growth strategy, HOPE Therapeutics has confirmed plans to acquire the Kadima Neuropsychiatry Institute in La Jolla, California. This acquisition, outlined in a previously announced Letter of Intent, positions Kadima as the flagship clinic in HOPE’s international network of interventional psychiatry practices.
Globally renowned for developing Ketamine Therapy for Central Nervous System (CNS) diseases, Kadima provides cutting-edge therapies for PTSD, anxiety, suicidal depression, and other CNS problems. These consist of TMS, Spravato (nasal esketamine), Ketamine Therapy, and complete pharmaceutical management. The research branch of Kadima is a leading investigative location in significant clinical trials and at the forefront of psychedelic therapeutic investigations.
Dedication to Veteran and Military Care
Additionally, Kadima treats active-duty military people under Tricare and other defense-related programs and has contracts with the US Department of Veterans Affairs; in line with HOPE’s objective to improve mental health services by using cutting-edge, research-proven treatments.
The goal of NRx Pharmaceuticals (NRXP) and HOPE Therapeutics’ strategic expansion is to strengthen their position as industry leaders in interventional psychiatry while promoting advancements in mental health care.
